GlassScriptPhysician profile
Dennis A Behler
NPI 1649593294
$3,441.09
in general payments reported to CMS, 2019-2025
36 companies · $966 in 2025
The $966 reported for 2025 was more than what 82% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $361 · 2022: $218 · 2023: $769 · 2024: $1,127 · 2025: $966.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,862.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,862.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $906.25 | 2021-2025 | Proclaim, Eterna |
| Abbvie INC. | $690.49 | 2022-2025 | |
| Novo Nordisk INC | $207.27 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $196.19 | 2023-2025 | |
| Dexcom, INC. | $140.99 | 2021-2025 | Dexcom G6 Transmitter |
| Astrazeneca Pharmaceuticals LP | $136.35 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Glaxosmithkline, LLC. | $118.22 | 2021-2024 | Trelegy Ellipta |
| Medtronic, INC. | $98.26 | 2022-2024 | Intellis Adaptivestim |
| Astellas Pharma US INC | $91.72 | 2024-2025 | Veozah |
| Antares Pharma, INC. | $84.88 | 2024-2025 | Xyosted |
| Corium, LLC | $74.44 | 2023-2024 | Azstarys |
| Lilly USA, LLC | $57.38 | 2025 | Zepbound, Mounjaro |
| Sanofi-Aventis U.S. LLC | $48.03 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $47.23 | 2024 | Trintellix |
| Vertex Pharmaceuticals Incorporated | $46.48 | 2025 |
Show all 36 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dennis Behler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.